Home > Name List By 5 > 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine Germany

CAS No 202409-33-4 , 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine Search by region : Germany

  • Name: 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
  • Synonyms: Arcoxia; MK 0663; Nucoxia; 202409-33-4; MK-663; Algix; Etoricoxibe; MK-0663; Tauxib;5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine;
  • CAS Registry Number:
  • Melting Point: 134-135 ºC
  • Density: 1.298 g/cm3
  • Refractive index: 1.6
  • Molecular Weight: 358.8419
  • InchiKey: MNJVRJDLRVPLFE-UHFFFAOYSA-N
  • InChI: InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-
    5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
  • Molecular Formula: C18H15ClN2O2S
  • Molecular Structure:CAS No:202409-33-4 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine

Related products

Select to

202409-33-4 Etoricoxib

  • Etoricoxib
  • Germany CHEMOS GmbH [Manufacturer]
  • Tel: 0049 9402/9336 0
  • Fax: 0049 9402/9336 13
  • Address: CHEMOS GmbH
    Werner-von-Siemensstr. 3
    93128 Regenstauf
    Germany null,nullGermany
Contact Supplier

Select to

1/1
References of 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
Title: Etoricoxib
CAS Registry Number: 202409-33-4
CAS Name: 5-Chloro-6￠-methyl-3-[4-(methylsulfonyl)phenyl]-2,3￠-bipyridine
Synonyms: 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine
Manufacturers' Codes: MK-663; MK-0663
Trademarks: Arcoxia (Merck & Co.)
Molecular Formula: C18H15ClN2O2S
Molecular Weight: 358.84
Percent Composition: C 60.25%, H 4.21%, Cl 9.88%, N 7.81%, O 8.92%, S 8.94%
Literature References: Selective cyclooxygenase-2 (COX-2) inhibitor. Prepn: D. Dube et al., WO 9803484; eidem, US 5861419 (1998, 1999 both to Merck Frosst); R. W. Friesen et al., Bioorg. Med. Chem. Lett. 8, 2777 (1998). Practical synthesis: I. W. Davies et al., J. Org. Chem. 65, 8415 (2000). HPLC determn in urine and plasma: C. Z. Matthews et al., J. Chromatogr. B 751, 237 (2001). Pharmacology: D. Riendeau et al., J. Pharmacol. Exp. Ther. 296, 558 (2001); A. Dallob et al., J. Clin. Pharmacol. 43, 573 (2003). Clinical comparison with indomethacin in acute gouty arthritis: H. R. Schumacher, Jr. et al., Br. Med. J. 324, 1488 (2002). Clinical trial in rheumatoid arthritis: A. K. Matsumoto et al., J. Rheumatol. 29, 1623 (2002); in osteoarthritis: S. P. Curtis et al., BMC Musculoskel. Disord. 6, 58 (2005); in ankylosing spondylitis: D. van der Heijde et al., Arthritis Rheum. 52, 1205 (2005). Gastrointestinal safety profile in inflammatory bowel diseases: Y. El Miedany et al., Am. J. Gastroenterol. 101, 311 (2006). Review of pharmacology and clinical development: P. Patrignani et al., Expert Opin. Pharmacother. 4, 265-284 (2003).
Properties: White solid, mp 127-128°. pKa 4.5. uv max (acetonitrile-phosphate buffer): 238, 280 nm.
Melting point: mp 127-128°
pKa: pKa 4.5
Absorption maximum: uv max (acetonitrile-phosphate buffer): 238, 280 nm
Therap-Cat: Anti-inflammatory; analgesic.
Keywords: Anti-inflammatory (Nonsteroidal); Cyclooxygenase-2 Selective Inhibitor; Analgesic (Non-Narcotic).